This article needs additional citations for verification. (February 2017) (Learn how and when to remove this template message)
|Headquarters||New York City, Pretoria|
Chief Executive Officer
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit product development partnership dedicated to the discovery and development of new, faster-acting and affordable tuberculosis medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.
Tuberculosis infects one third of the world’s population, kills approximately 1.5 million people each year, and costs the global economy $16 billion annually. However, research and development for new TB drugs came to a virtual standstill after the 1960s. Today, a four drug combination therapy exists, but it takes six months or more to be effective. This requires a degree of monitoring (See Direct Observational Therapy, Shortcourse) beyond the capacity of the health infrastructure in many countries; adequate TB treatment is available to less than half of the most infectious cases. This can inhibit control of the disease and fuel the rise of drug resistance. TB is also the number one killer of AIDS patients, but it is generally agreed that current TB treatments do not work well with the antiretroviral drugs used to treat HIV.
The TB drug market lacks sufficient financial incentives to stimulate a single private pharmaceutical company to invest in the new research required to sustain a treatment pipeline. The TB epidemic is concentrated in developing countries where drugs must be low in cost to remain accessible. It does not generate the kind of revenue streams that private companies usually deem necessary to justify the research costs and strategic risks involved in pharmaceuticals. The TB Alliance was designed to be the primary instrument to fill this vacuum and to ensure that new anti-TB drugs are affordable and accessible in endemic countries.
The TB Alliance was conceived at a February 2000 meeting in Cape Town, South Africa, where 120 representatives from academia, industry, major government agencies, non-governmental organizations and donors gathered to discuss the problems of tuberculosis treatment. Participants stressed the need for faster-acting, novel TB drugs and highlighted the scientific opportunities involved. The resulting "Declaration of Cape Town" provided a road map for TB drug development and outlined the need for creation of the TB Alliance. Maria Freire was appointed as the first Chief Executive Officer and President in 2001 and served in that capacity until 2008, when she left the TB Alliance to become President of the Lasker Foundation. The current CEO and President is Melvin Spigelman.
The TB Alliance is a non-profit public-private partnership. It operates like a virtual biotechnology firm, collaborating with research institutions and pharmaceutical companies so that risks and incentives are shared. While retaining management oversight of its drug development projects, the TB Alliance out-sources the development of potential drugs to public and private partners, providing funding and scientific guidance. Depending on the project, the TB Alliance either co-invests and co-develops a project, funds and manages it directly, or in-licenses the technology or intellectual property involved. Project diversity is a stated goal, with potentials compounds selected from a variety of chemical classes, with a wide range of targets within the TB organism, Mycobacterium tuberculosis.
In January 2009, the TB Alliance had 16 drug projects underway, either in either discovery or clinical or phase. Part of the TB Alliance’s stated mission is to ensure that any new treatments are affordable and accessible in the developing world, and that they are adopted as soon as they become available. Pricing terms are included in all licensing contracts and end products are designed to be easy to take. The TB Alliance also collaborates with national and international partners, working to ensure that new therapies are adopted and accessible to healthcare providers and patients via local channels.
Adverse effects and patient compliance
Some anti-tuberculosis agents are known to have some side effects, which limits their use for mono-therapies only. This poses a limitation for their use in combination therapy, for overcoming drug resistance. Also, some of the side effects may lead to a low level of compliance by the patient, i.e. not completing the full course of treatment. This creates conditions within the patient that enable drug resistance to arise or even to become prevalent. In view of such situations it is often recommended that novel anti-tuberculosis agents need to be discovered and developed.
Drug resistance occurs for several reasons, often as a natural consequence of gene mutations and selection, as a consequence of drug-efflux mechanisms, or due to drug modifying enzymes. Under conditions of medical treatment, mutants that are resistant to the drug may escape the drug's action, survive and multiply further. This is one of the reasons why combination therapies are often essential for treating tuberculosis infections and most infectious diseases. At the present time, three of even four tuberculosis drugs are given as a combination therapy, over an extended period of time, though patient compliance and side effects continue to be a medical issue. Some strains of the tuberculosis pathogen are resistant to all three or four tuberculosis drugs. In view of the contagious nature of tuberculosis, especially among persons with weak immunity, drug resistance is considered to be a serious public health issue.
Investigational New Drugs
Investigational new drugs (IND) are clinical candidates that are safe and efficacious in the animal models of infection. Usually, these are new chemical entities (NCE) with a novel mechanism of action. Investigational new drugs have to be approved by the national or international medical regulatory authorities, for clinical testing and development in humans.
IND's are usually discovered and developed to overcome the limitations of drugs that are or have been in clinical use.
The TB Alliance has a diverse set of global partnerships with both public and private sector donors that fund the company’s work. The organization operates with the support of:
- Australian Aid (AusAID)
- Bill & Melinda Gates Foundation
- Dutch Ministry of Foreign Affairs (DGIS)
- Federal Ministry of Education and Research
- Global Health Innovative Technology (GHIT) Fund
- Indonesia Health Fund
- Irish Aid
- UK Aid
- UK Department of Health
- United States Agency for International Development (USAID)
- United States Food and Drug Administration (FDA)
- "Clinical Portfolio | TB Alliance". www.tballiance.org. Retrieved 2017-06-20.
- "Home | TB Alliance 2016 Annual Report". TB Alliance 2016 Annual Report. Retrieved 2017-06-20.
- "Tuberculosis Data and Statistics". www.cdc.gov. Retrieved 2 May 2016.
- "Tuberculosis Data and Statistics". www.cdc.gov. Retrieved 2 May 2016.
- "The Cape Town Declaration of the Working Alliance for TB Drug Development" (PDF). www.tballiance.org. Cape Town, South Africa. February 8, 2000.
- "Global Alliance for TB Drug Development Appoints Respected Scientist and Director of R&D as New Chief Executive". www.tballiance.org. Retrieved 9 October 2008.
- "Donors". TB Alliance. Retrieved 2017-06-20.